Immunoliposomes for Neuroblastoma: Review of the Past Experience and Design of a Novel Nanoparticle
Anticancer Research · 2024
DOI: 10.21873/anticanres.17294 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Anticancer Research, 2024. Verfasst von William S Panosyan und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of California Los Angeles, UCLA College of Letters & Science, Los Angeles, CA, U.S.A. williampanosyan@ucla.edu. Hauptthemen laut MEDLINE: Neuroblastoma, Liposomes, Nanoparticles. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND/AIM: High-risk/refractory neuro-blastoma (NBL) treatments include anti-GD2-monoclonal antibodies (mAbs). Several immunoliposomes (ILs) covered with anti-GD2-mAbs (GD2-ILs) have been tested pre-clinically. We aimed to review literature on GD2-IL for characteristics of nanoparticles/payloads, conjugation of mAb/fragments and preclinical data, as well as to explore the feasibility of a recently proposed GD2-IL loaded with the antimetabolite oxamate. MATERIALS AND METHODS: Initial PubMed search was generalized for immunoliposomes in cancer. Further search was focused on papers for GD2-IL [keywords: "Immunoliposomes and cancer (or neuroblastoma)"]. RESULTS: There were 811 results on "immunoliposomes"; >50% were on "immunoliposomes, cancer" (n=439, June 2024). Seventeen items resulted from "immunoliposomes, neuroblastoma" (one was "publishers' correction"). Sixteen GD2-IL references were reviewed (1993-current). The mean±SD GD2-ILs size was 124.8±31 nm (range=86-171). Six papers described GD2-ILs with DNA-damaging agents [doxorubicin (n=4), etoposide (n=1), irinotecan+HDAC inhibitor (n=1)]. Other payloads included: fenretinide (n=4 papers), C-myb antisense (n=2), survivin inhibitor (n=1), tyrosine kinase inhibitor (n=1), IL15 (n=1), and oxamate (n=1). These 9 drug-loads included both hydrophilic and hydrophobic molecules. Except for IL15 and C-myb antisense with high molecular weights (MWs), and oxamate with low MW, the remaining compounds had comparable MWs (496±100 g/mol, range=349-588.6). The overall encapsulation efficiency was 66.2±25.6%. There were 17-30 mAb molecules attached to an IL with PEGylation. Experiments with GD2-positive/GD2-negative cells demonstrated selective efficacy/tropism of GD2-ILs. Mouse models confirmed efficacy, GD2-specific tumor accumulation, decreased toxicity, and improved pharmacokinetic-pharmacodynamics. CONCLUSION: PEGylated anti-GD2-IL may allow NBL tropism. A size of approximately 100 nm could allow vascular permeability and packaging of oxamate in amounts needed for profound/selective lactate dehydrogenase-A inhibition. Thus, oxamate-loaded GD2-ILs may allow exploring the great translational potential of Warburg effect inhibition in GD2-positive cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of California Los Angeles, UCLA College of Letters & Science, Los Angeles, CA, U.S.A. williampanosyan@ucla.edu.
- University of California Los Angeles, UCLA College of Letters & Science, Los Angeles, CA, U.S.A.
Zitieren
APA
Panosyan, W. S., & Panosyan, D. E. (2024). Immunoliposomes for Neuroblastoma: Review of the Past Experience and Design of a Novel Nanoparticle. Anticancer Research. https://doi.org/10.21873/anticanres.17294
Vancouver
Panosyan WS, Panosyan DE. Immunoliposomes for Neuroblastoma: Review of the Past Experience and Design of a Novel Nanoparticle. Anticancer Research. 2024. doi:10.21873/anticanres.17294
BibTeX
@article{Panosyan2024,
author = {Panosyan, William S and Panosyan, Daniel E},
title = {Immunoliposomes for Neuroblastoma: Review of the Past Experience and Design of a Novel Nanoparticle},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.17294}
}
EUVIMED